Humacyte to Participate at Upcoming Investor Conferences in September
Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology company, has announced its participation in two upcoming investor conferences in September 2024. The company, which focuses on developing universally implantable, bioengineered human tissue at commercial scale, will be represented by Laura Niklason, M.D., Ph.D., Founder, President, and CEO, and Dale Sander, CFO.
The conferences are:
- H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 11, 2024, from 8:30 - 9 AM ET
- Cantor Global Healthcare Conference on Wednesday, September 18, 2024, from 9:10 - 9:40 AM ET
Both events will feature company presentations, with webcasts available for interested parties to view online.
Humacyte (Nasdaq: HUMA), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione a due prossimi conferenze per investitori nel settembre 2024. L'azienda, che si concentra nello sviluppo di tessuti umani bioingegnerizzati universalmente impiantabili su scala commerciale, sarà rappresentata da Laura Niklason, M.D., Ph.D., Fondatrice, Presidente e CEO, e Dale Sander, CFO.
Le conferenze sono:
- 26a Conferenza Annuale Globale sugli Investimenti H.C. Wainwright martedì 11 settembre 2024, dalle 8:30 alle 9:00 AM ET
- Conferenza Sanitaria Globale Cantor mercoledì 18 settembre 2024, dalle 9:10 alle 9:40 AM ET
Entrambi gli eventi presenteranno presentazioni aziendali, con webcast disponibili per le parti interessate da visualizzare online.
Humacyte (Nasdaq: HUMA), una empresa biotecnológica en etapa clínica, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024. La empresa, que se enfoca en el desarrollo de tejidos humanos bioingenierizados, implantables de forma universal a gran escala, será representada por Laura Niklason, M.D., Ph.D., Fundadora, Presidenta y CEO, y Dale Sander, CFO.
Las conferencias son:
- 26ª Conferencia Anual Global de Inversiones H.C. Wainwright el martes 11 de septiembre de 2024, de 8:30 a 9:00 AM ET
- Conferencia Global de Atención Médica Cantor el miércoles 18 de septiembre de 2024, de 9:10 a 9:40 AM ET
Ambos eventos presentarán presentaciones de la empresa, con webcasts disponibles para que las partes interesadas las vean en línea.
Humacyte (Nasdaq: HUMA)는 임상 단계의 생명공학 회사로, 2024년 9월에 열리는 두 개의 투자자 컨퍼런스에 참여할 예정이라고 발표했습니다. 상업적 규모로 보편적으로 이식 가능한 생체 공학 인체 조직 개발에 주력하는 이 회사는 Laura Niklason, M.D., Ph.D. (창립자, 대통령, CEO)와 Dale Sander (CFO)가 참석합니다.
컨퍼런스 일정은 다음과 같습니다:
- H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스 2024년 9월 11일 화요일, 오전 8:30 - 9:00 ET
- 캔터 글로벌 헬스케어 컨퍼런스 2024년 9월 18일 수요일, 오전 9:10 - 9:40 ET
두 행사 모두 기업 발표가 있으며, 이해 관계자들이 온라인으로 시청할 수 있는 웹캐스트가 제공됩니다.
Humacyte (Nasdaq: HUMA), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024. L'entreprise, qui se concentre sur le développement de tissus humains bioingénierisés implantables universellement à grande échelle, sera représentée par Laura Niklason, M.D., Ph.D., Fondatrice, Présidente et CEO, et Dale Sander, CFO.
Les conférences sont:
- 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright le mardi 11 septembre 2024, de 8h30 à 9h00 ET
- Conférence Mondiale sur la Santé Cantor le mercredi 18 septembre 2024, de 9h10 à 9h40 ET
Les deux événements présenteront des présentations de l'entreprise, avec des webcasts disponibles pour que les parties intéressées puissent les visionner en ligne.
Humacyte (Nasdaq: HUMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen, das sich auf die Entwicklung von universell implantierbarem, bioengineering menschlichem Gewebe in kommerziellen Maßstab konzentriert, wird vertreten durch Laura Niklason, M.D., Ph.D., Gründerin, Präsidentin und CEO, sowie Dale Sander, CFO.
Die Konferenzen sind:
- 26. Jährliche Globale Investorenkonferenz H.C. Wainwright am Dienstag, den 11. September 2024, von 8:30 bis 9:00 Uhr ET
- Cantor Globale Gesundheitskonferenz am Mittwoch, den 18. September 2024, von 9:10 bis 9:40 Uhr ET
Beide Veranstaltungen beinhalten Unternehmenspräsentationen, und Webcasts sind für interessierte Parteien online verfügbar.
- None.
- None.
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following conferences in September.
H.C. Wainwright 26th Annual Global Investment Conference
Format: Company Presentation
Date: Tuesday, September 11, 2024
Time: 8:30 – 9 AM ET
Webcast: https://journey.ct.events/view/
Cantor Global Healthcare Conference
Format: Company Presentation
Date: Wednesday, September 18, 2024
Time: 9:10 – 9:40 AM ET
Webcast: https://wsw.com/webcast/cantor22/huma/
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When is Humacyte (HUMA) presenting at the H.C. Wainwright Global Investment Conference in 2024?
What is the date and time for Humacyte's (HUMA) presentation at the Cantor Global Healthcare Conference in 2024?
Who will be representing Humacyte (HUMA) at the September 2024 investor conferences?
What is Humacyte's (HUMA) main focus as a biotechnology company?
Are webcasts available for Humacyte's (HUMA) investor conference presentations in September 2024?
